Of note, within individual patients, HER2 and ESR1 subclonal mutations appeared at different allele frequencies, raising the possibility that these two distinct resistance mechanisms contribute toward the full complement of drug resistance in heterogeneous tumor populations (Table 2). The gene discussed is ESR1; the disease is neoplasm.